ABSTRACT
Background Sexual and gender expansive (SGE) individuals in Kazakhstan are disproportionately affected by HIV yet stigma and discrimination pose ethical and practical challenges for HIV prevention research involving them. Although researchers are tasked with ensuring that risks of research participation are reasonable in relation to its benefits, participation-related risks and benefits—including negative and positive social impacts (NSIs and PSIs respectively) on personal relationships, social status, health, and other aspects of life—among SGE populations have received little attention.
Methods We examined NSIs and PSIs of participation among SGE individuals in a three-city HIV prevention study in Kazakhstan at the clinical trial’s follow-up visits. We analyzed responses from 579 unique SGE participants who completed a total of 2648 follow-up visits over the 36-month study period (2019–2022).
Results Overall, NSIs were rare: 9 (2%) participants reported NSIs during the study; virtually no NSIs (x̅=0.0037, SD=0.03) were reported at each follow-up visit. These few NSIs included ‘trouble with friends, family, or acquaintances’ and ‘other’. By contrast, PSIs were extensive: 515 (89%) participants reported PSIs during the study; almost an average of five PSIs (x̅=4.8, SD=3.4) were reported at each follow-up visit. The most endorsed PSIs were ‘gained knowledge’, ‘improvement in HIV-related issues’, and ‘improvement in life’.
Conclusions Our findings demonstrate the potential for HIV prevention research to be associated with PSIs for SGE individuals experiencing stigmatization and discrimination. Future research should address NSIs, particularly interpersonal challenges among network members, within HIV prevention research to minimize risks and burdens of participation.
ClinicalTrials.gov: NCT02786615
Competing Interest Statement
Jeremy Sugarman is a member of Merck KGaA Ethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA's Ethics Advisory Panel; a member of Aspen Neurosciences Clinical Advisory Panel; and a consultant to Merck. None of these activities is related to the material discussed in this manuscript. The other authors have no competing financial or non-financial interest to declare.
Clinical Trial
NCT02786615
Funding Statement
This study was supported by the National Institute on Drug Abuse [grant R01DA040513 (PI: Wu)]. Emily Allen Paine's time was supported by the National Institute of Mental Health [grants K01MH128117 (PI: Paine) and P30MH43520 (PI: Remien)].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of Columbia University and Al-Farabi Kazakh National University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
